Avanir cites 'en­cour­ag­ing' progress in PhI­II pro­gram for Alzheimer's ag­i­ta­tion

Avanir Phar­ma has chalked up a win for the first late-stage study for AVP-786 in Alzheimer’s ag­i­ta­tion, lay­ing the ground­work for a high-risk, high-re­ward Phase …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.